<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373917</url>
  </required_header>
  <id_info>
    <org_study_id>Lung-RND-001</org_study_id>
    <nct_id>NCT02373917</nct_id>
  </id_info>
  <brief_title>Characterization of Methylation Patterns in Lung Cancer</brief_title>
  <official_title>Characterization of Methylation Patterns in Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nucleix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will collect Blood,sputum and saliva samples for&#xD;
      Characterization of Methylation Patterns in lung Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lots of information about the relationship between changes in methylation patterns and&#xD;
      various diseases are accumulated in recent years. Characterization of methylation changes&#xD;
      that occur in cancer may contribute to the development of methods for early detection of&#xD;
      cancer by detecting cancer cells in liquids. Early detection of such changes and their&#xD;
      correlation examining different cancers may lead to a diagnostic tool for the early detection&#xD;
      of cancers and improve the treatment of these patients. Detection by molecular analysis can&#xD;
      be a sensitive method and non-invasive early diagnosis of the disease In this study the&#xD;
      investigators will collect Blood,sputum and saliva samples for Characterization of&#xD;
      Methylation Patterns in lung Cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of Methylation Patterns in lung Cancer</measure>
    <time_frame>two years</time_frame>
    <description>Collecting and analyzing samples</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">683</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <description>patient who in the biopsy showed lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>patient who in the biopsy showed not to have lung cancer</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Blood samples&#xD;
&#xD;
        2. Sputum samples&#xD;
&#xD;
        3. saliva samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who come to the medical center for the diagnosis of lung cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected lung tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have active disease other than lung cancer during the sample collecting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eilon Ganor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nucleix Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sha'are Tzedaek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

